Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Burton M. Needles"'
Autor:
Burton M. Needles
Publikováno v:
Cold Spring Harbor Molecular Case Studies
In 2013, the American Association for Cancer Research (AACR) introduced the “Precision Medicine Series” of symposia. The goal of these conferences is to “highlight the incredible technology and advances in cancer research that together are enab
Autor:
Carole Seigel, Simon J. Craddock Lee, John Cox, Burton M. Needles, Bijal A. Balasubramanian, Mark A. Clark
Patients with cancer with multiple chronic conditions pose a unique challenge to how primary care and specialty care teams provide well-coordinated, patient-centered care. Effectiveness of these care teams in providing optimal health care depends on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1217d55f6eab3f78a52e1f3241c76ee5
https://europepmc.org/articles/PMC5356468/
https://europepmc.org/articles/PMC5356468/
Autor:
E. David Crawford, Mario A. Eisenberger, Burton M. Needles, Neel Hammond, Thomas E. Seay, Robert C. Flanigan, Danika Lew, Louis E. Schroder
Publikováno v:
Urologic Oncology: Seminars and Original Investigations. 6:145-148
Twenty-two eligible patients with advanced renal carcinoma were treated with suramin utilizing a fixed dose regimen. Therapy was reasonably well tolerated with 3 of 22 patients (14%) developing grade 4 toxicity and 11 of 22 patients (50%) having a ma
Autor:
Teresa L. Dunleavy, Kathryn Trinkaus, Bruce R. Harrison, Han J. Kim, Frank R. Dunphy, Brendan C. Stack, Burton M. Needles, James H. Boyd
Publikováno v:
Cancer. 91:940-948
BACKGROUND After standard therapy for advanced head and neck carcinoma, 5-year survival rate is less than 50%. Our purpose was to develop a new treatment for advanced head and neck carcinoma by using preoperative chemotherapy. Long term efficacy and
Autor:
Luis Baez Diaz, Janice Brogden, Michael Ames, Jesse I. Spector, Eduardo Miranda, Burton M. Needles, Francisco M. Garcia Rodriguez, Steven H. Krasnow, Gary I. Cohen, Johnny Craig
Publikováno v:
Supportive Care in Cancer. 7:347-353
The objectives of this study were to compare the efficacy and safety of orally administered ondansetron 8 mg b.i.d., 24 mg q.d., and 32 mg q.d. in the prevention of nausea and vomiting associated with high-dose cisplatin-based chemotherapy (cisplatin
Autor:
Roy E. Smith, Reena S. Cecchini, David Cella, Eduardo R. Pajon, Michael O’Connell, Burton M. Needles, Thomas E. Seay, Jacek A. Kopec, Norman Wolmark, Patricia A. Ganz, Linda H. Colangelo, J. Philip Kuebler, James D. Bearden, Lauren K. Colman, Stephanie R. Land, Keith S. Lanier, Joseph P. Costantino, H. Samuel Wieand, Kate Murphy
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(16)
Purpose The randomized, multicenter, phase III protocol C-07 compared the efficacy of adjuvant bolus fluorouracil and leucovorin (FULV) versus FULV with oxaliplatin (FLOX) in stage II or III colon cancer. Definitive analysis revealed an increase in 4
Autor:
James Piephoff, Nicholette Erickson, Volker W. Stieber, Edward G. Shaw, Monica Loghin, Michelle J. Naughton, Burton M. Needles, Stephen R. Rapp, Steven Charles Falchuk, Paul A. Bilodeau, William Jeffery Edenfield, Gerald K. Bayer, Dennis F. Moore, Doug Case, Jeffrey K. Giguere
Publikováno v:
Journal of Clinical Oncology. 31:2051-2051
2051 Background: Cognitive problems after cancer therapy can decrease QOL. This phase III randomized trial tested the effect of donepezil (5-10 mg daily for 24 weeks) on cognition and QOL in brain cancer patients. Methods: Between 2/2008-12/2011, 198
Autor:
William Jeffery Edenfield, Dennis F. Moore, James Piephoff, Doug Case, Monica Loghin, Jeffrey K. Giguere, Ann M. Peiffer, Edward G. Shaw, Paul A. Bilodeau, Burton M. Needles, Michelle J. Naughton, Nicholette Erickson, Volker W. Stieber, Stephen R. Rapp, Steven Charles Falchuk, Gerald K. Bayer
Publikováno v:
Journal of Clinical Oncology. 31:2006-2006
2006 Background: This RCT assessed the effect of 24 weeks of 5-10 mg per day of donepezil, an acetyl cholinesterase inhibitor, on cognitive functioning (primary endpoint) and fatigue, mood and QOL in long-term brain tumor survivors following partial
Autor:
Burton M. Needles
Publikováno v:
Journal of Clinical Oncology. 13:1047-1047
To the Editor: I am writing to alert readers to a dosing error in the book, The Chemotherapy Handbook, published and distributed by Cerenex Pharmaceuticals. On page 85, in the Urogenital Cancer section, the correct bleomycin dose for the bleomycin/et